Dipeptidyl peptidase 4 inhibitors in modern domestic practice

The choice of treatment of diabetes mellitus type 2 is personalized, based on modern Russian and international algorithms for management of such patients. Given the initial level of decompensation of the disease at the time of diagnosis (at the level of glycated hemoglobin), most patients with type 2 diabetes at the time of initiation of therapy requires the combined treatment, at least two antidiabetic drugs. In modern conditions, on the basis of evidence-based medicine, priority should be given to drugs with a low risk of hypoglycemic conditions and do not affect or reduce body weight. In this article we consider a class of inhibitors of dipeptidyl peptidase 4, which entered into clinical practice since 2006 for the treatment of patients suffering from diabetes mellitus type 2, with an emphasis on drugs used in the Russian Federation. Today in our country there are seven members of the class of inhibitors of dipeptidyl peptidase 4. The results of the major randomized clinical trials (SAVOR-TIMI 53, EXAMINE, TECOS, CAROLINA), which studied the cardiovascular safety of dipeptidyl peptidase 4 inhibitors, showed the intra class heterogeneity with respect to data on the frequency of hospitalizations due to chronic heart failure. Have proven cardiovascular neutrality in relation to the primary combined cardiovascular outcome was MACE, including cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. A major problem is the choice of effective glucose-lowering therapy to special patient groups. Assign their profession the safety of drugs plays a key role. With its high efficiency and unique glucosidation mechanism of action, guaranteeing a low risk of hypoglycemia and high safety, the drugs of this group has firmly taken its niche among the priority hypoglycemic drugs.

1. Nedosugova L.V., Petunina N.A. Combined Oral Hypoglycemic Therapy: an Effective and Safe Choice. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2019;(5):58–64. (In Russ.) Available at: https://umedp.ru/articles/kombinirovannaya_peroralnaya_sakharosnizhayushchaya_terapiya_effektivnyy_i_bezopasnyy_vybor.html.

2. Simon D., de Pablos-Velasco P., Parhofer K.G., Gönder-Frederick L., Duprat Lomon I., Vandenberghe H. et al. Hypoglycaemic episodes in patients with type 2 diabetes – risk factors and associations with patient-reported outcomes: The PANORAMA Study. Diabetes Metab. 2015;41(6):470–479. doi: 10.1016/j.diabet.2015.08.007.

3. Nishioka Y., Okada S., Noda T., Myojin T., Kubo S., Ohtera S. et al. Absolute risk of acute coronary syndrome after severe hypoglycemia: A populationbased 2-year cohort study using the National Databased in Japan. J Diabetes Investig. 2020;11(2):426–434. doi: 10.1111/jdi.13153.

4. Dedov I.I., Shestakova M.V., Majorov A.Yu. (eds.). Standarts of specialized diabet care. 9th ed. (revised). Sakharni Diabet = Diabetes Mellitus. 2019;22(1):1–144. (In Russ.) doi: 10.14341/DM221S1.

5. American Diabetes Association. Standards of Medical Care in Diabetes –2020. Diabetes Care. 2020;43(1):1–2. doi: 10.2337/dc20-Sint.

6. Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu Ch. et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi: 10.2337/dci19-0066.

7. Lazareva N.B. Dipeptidyl dipeptidase-4: view of the clinical pharmacologist. Meditsinskiy sovet = Medical Council. 2016;(19):114–121. (In Russ.) doi: 10.21518/2079-701X-2016-19-114-121.

8. Chorbinskaya S.A., Petunina N.A., Trunina Ye. N. Advanced treatment modalities in patients with type 2 diabetes mellitus. Kremlevskaya medicina. Klinicheskij vestnik = Kremlin Medicine Journal. 2014;(1):90–95. (In Russ.) Available at: http://kremlin-medicine.ru/index.php/km/article/view/473.

9. Morgunova T.B., Fadeyev V.V. Dipeptidyl peptidase-4 inhibitors use in clinical practice. Consilium Medicum. 2019;21(4):40–44. (In Russ.) doi: 10.26442/20751753.2019.4.190349.

10. Cahn A., Cernea S., Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opinion on Emerging Drugs, 2016;21(4):409–419. doi: 10.1080/14728214.2016.1257608.

11. Scirica B.M., Braunwald E., Raz I., Cavender M.A., Morrow D.A., Jarolim P. et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. doi: 10.1161/CIRCULATIONAHA.114.010389.

12. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684.

13. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L. et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889.

14. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.

15. Santamarina M., Carlson C.J. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. BMC Cardiovasc Disord. 201915;19(1):60. doi: 10.1186/s12872-019-1036-0.

16. McInnes G., Evans M., Del Prato S., Stumvoll M., Schweizer A., Lukashevich V., Shao О., Kothny W. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085–1092. doi: 10.1111/dom.12548.

17. Ametov A. The National Diabetes Register should become a tool for import substitution. Remedium. 2018;(11):25–28. (In Russ.) Available at: http://www.remedium-journal.ru/upload/iblock/624/RM_011_2018_4.pdf

18. Galstyan K.O., Nedosugova L.V., Petunina N.A., Trakhtenberg J.A., Vostokova N.V., Karavaeva O.V., Chasovskaya T.E. First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients. Sakharnyy diabet = Diabetes mellitus. 2016;19(1):89–96. (In Russ.) doi: 10.14341/DM7233.

19. Biryukova E.V. Clinical aspects and prospects of using DPP-4 inhibitors. Meditsinskiy sovet = Medical Council. 2019;(4):24–29. (In Russ.) doi: 10.21518/2079-701X-2019-4-24-29.

20. Karagiannis T., Paschos P., Paletas K., Matthews D.R., Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369. doi: 10.1136/bmj.e1369.

21. Gariyeva M.A., Kondrat’yeva L.V., Chernikova N.A. Glycemic variability in patients with type 2 diabetes working on night shifts. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Training. 2019;8(2):16–24. (In Russ.) doi: 10.24411/2304-9529-2019-12002.